MedTrace Logo

Closing the Loop in Adults With Type 1 Diabetes in the Home Setting

NCT01440140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-01-29

No results posted yet for this study

Summary

The main study objective is to compare real-time continuous subcutaneous glucose monitoring (CGM) combined with overnight automated closed-loop glucose control, and real-time CGM alone in the home setting.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

OTHER

Closed-loop

Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.

OTHER

Conventional insulin pump delivery

Subcutaneous delivery of Novorapid insulin according to usual pump regime

Sponsors & Collaborators

Principal Investigators

  • Roman Hovorka, PhD, MSc, BSc · University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01440140 on ClinicalTrials.gov